12.         Stock-based Compensation

Shares available for grant

On May 16, 2025, the Company held its 2025 Annual Meeting of Stockholders (the "Annual Meeting") and ratified an amendment to the Company's Amended and Restated 2014 Equity Incentive Plan (the "2014 Plan") to increase the total number of shares of common stock authorized for issuance by 153 shares. As of June 30, 2025, the total number of shares authorized for grant under the 2014 Plan was 468, of which 128 were available for future grants.

Restricted Stock Units

The Company issues time-based restricted stock units (“RSUs”) and performance-based restricted stock units ("PSUs") to employees and non-employees. Each RSU and PSU represents the right to receive one share of the Company’s common stock upon vesting and subsequent settlement. PSUs vest upon achievement of performance targets based on the Company's annual operating plan. The fair values of RSUs and PSUs are determined based on the closing price of the Company’s common stock on the date of grant.

RSU activity for the six months ended June 30, 2025 is summarized below:

As of June 30, 2025, $637 of total unrecognized compensation expense related to unvested RSUs was expected to be recognized over a weighted average period of 1.17 years.

There was no PSU activity for the six months ended June 30, 2025.

Stock Options

The following table summarizes information about the Company's stock options outstanding as of June 30, 2025, and activity for the six months ended  June 30, 2025:

No stock options were exercised during the three and six months ended June 30, 2025 and 2024.

The total grant-date fair value of stock options vested during the three and six months ended June 30, 2025 and 2024 was $0.

As of June 30, 2025, total unrecognized compensation cost related to unvested stock options was $0.

Compensation Expense

Stock-based compensation expense is included in the condensed consolidated statements of operations and comprehensive loss in general and administrative, research and development, or sales and marketing expenses, depending on the nature of the services provided. Stock-based compensation expense related to RSUs and PSUs was recorded as follows:

401(k) Plan Share Match

During the six months ended June 30, 2025 and 2024, the Company issued 37 and 11 shares of common stock with a fair value of $236 and $238, respectively, to eligible employees’ deferral accounts for the Ekso Bionics 401(k) plan (the "401(k) Plan") matching contribution representing 50% of each eligible employee’s elected deferral (up to the statutory limit) for the years ended December 31, 2024 and 2023.

The expense, net for the 401(k) Plan share matching was $15 and $113 for the six months ended June 30, 2025 and 2024, respectively.